13D/13G Filings - Replimune Group Inc. (REPL)

Real time Form 13D and 13G transaction reports:

  • Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
  • Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
  • Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
Time period
Goto Prev, 0, 1, 2
Reported
DateTime
Transaction
Date
TypeCompany
Symbol
Filed By
Symbol
Shares Owned
% Owned
Shares Vs. Prev ReportView
2021-02-11
5:12 pm
Sale
2020-12-3113GReplimune Group, Inc.
REPL
BIOTECHNOLOGY VALUE FUND L P0
0.000%
-2,309,109decrease
(Position Closed)
Filing
History
2021-02-08
10:31 am
Purchase
2021-02-0513GReplimune Group, Inc.
REPL
FMR LLC2,626,417
5.714%
2,626,417increase
(New Position)
Filing
History
2020-09-17
4:50 pm
Sale
2020-09-1513DReplimune Group, Inc.
REPL
Atlas Venture Fund X L.P.2,524,866
6.300%
-436,607decrease
(-14.74%)
Filing
History
2020-07-07
5:11 pm
Sale
2020-07-0213DReplimune Group, Inc.
REPL
Atlas Venture Fund X L.P.2,961,473
7.500%
-436,607decrease
(-12.85%)
Filing
History
2020-06-19
5:03 pm
Sale
2020-06-1613DReplimune Group, Inc.
REPL
Atlas Venture Fund X L.P.3,398,080
8.600%
-436,507decrease
(-11.38%)
Filing
History
Goto Prev, 0, 1, 2